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While the true mortality rate from COVID-19 seems to be a moving target, rationing essential 
medical equipment, protecting medical personnel, and planning for maximal hospital 
occupancy is a real daily reality. As colorectal surgeons, we do not personally manage 
ventilators or cases of acute respiratory distress syndrome (ARDS), but we are faced with an 
imminent reality of redeployment to medical, and/or ICU care. While many of us have not 
intubated a patient since residency, we will undoubtedly strive to apply any medical care that 
is needed. Surprisingly, we may be able to also apply our knowledge of novel therapeutics to 
the COVID-19 crisis, finding ourselves in a position to actually help these patients, despite 
our focus on colorectal pathology. Mesenchymal stem cells (MSCs), which have now 
demonstrated safety and efficacy for perianal Crohn’s disease across several phase I,1–5 phase 
II,4,6,7 and phase III8 clinical trials, act as a potent anti-inflammatory and immunomodulatory 
agent. Just as Crohn’s disease is characterized by increased inflammatory cytokines and 
aberrant ratios of immune cells (ie, decreased number of T-regulatory cells and increased 
proinflammatory M1 macrphoages), COVID-19 patients also exhibit hyperinflammation with 
a cytokine storm and recruitment of immune cells that result in an ARDS picture. Thus, the 
purpose of this review is to help colorectal surgeons apply our experience with MSCs to 
COVID-19. 
COVID-19 Problem 
The outbreak of coronavirus (COVID-19) has led to a rapid increase in morbidity and 
mortality due to ARDS worldwide. ARDS is the most common complication in COVID-19 
patients. This is thought to be due to a rapid cytokine cascade within a short period of time 
resulting in severe inflammation, which creates an increase in lung endothelial and epithelial 
permeability.9 This severe proinflammatory response results in lung damage, impaired gas 
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ARDS is high at 30-40%.10–12 Despite extensive investigation of therapeutic strategies for 
managing ARDS, the current standard of care is largely supportive with lung-protective 
ventilation and a fluid conservative strategy.9 Despite advances in lung-protective ventilation 
and fluid management, a high age-related mortality rate remains. 
COVID-19 infected patients who develop ARDS are typically older with comorbidities, but 
no age group or health-status has been spared as COVID has crossed the globe. In ARDS, 
severe lung inflammation is thought to be sustained by elevated proinflammatory cytokines 
including interleukin (IL)-6, IL 1, IL 8, tumor necrosis factor-α (TNF-α) and as noted by 
elevated levels of serum C- reactive protein (CRP). The mortality rate in COVID-19 related 
severe ARDS is quite high despite treatment with antivirals, glucocorticoids, 
immunoglobulins, and ventilation. Preclinical and clinical evidence indicate that MSCs 
migrate to the lung and respond to the proinflammatory lung environment by releasing anti-
inflammatory factors reducing the proliferation of proinflammatory cytokines noted above 
while modulating regulatory T-cells and macrophages to promote resolution of inflammation. 
Therefore, MSCs have potential to increase survival in management of ARDS. 
MSCs Have Actually Already Been Useful 
Two studies from China have already shown MSCs to be a relevant player in the 
armamentarium of proposed therapeutics for COVID-19. The first was a case report of a 
critically ill COVID-19 patient on a ventilator who had progressed despite intensive therapy 
with concurrent liver injury. The patient was treated with allogeneic human umbilical cord 
MSCs using three intravenous infusions of 5 × 107 cells, each three days apart. Within four 
days of the first MSC infusion, the patient was extubated and able to walk. All measured 
parameters, including circulating T cell counts, returned to normal levels. No obvious side 
effects were observed.13 The second study was a study from Wuhan of 7 patients that 
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that the treatment was well tolerated, and all seven patients were able to be extubated. All 
treated patients had confirmed COVID-19 and had symptoms of high fever, shortness of 
breath, weakness, and low O2 saturation (<95%) (Table 1).14 Within 2 to 4 days after MSC 
treatment, all symptoms disappeared, and O2 saturation increased. Clinical improvement was 
presumably associated with a reduction in inflammatory cytokines as the reduction in CRP in 
the most severely affected patient was 191 g/L to 10.1 g/L following treatment. In addition, 
after the intravenous administration of MSCs, serum levels of the proinflammatory cytokine 
TNF-α decreased significantly, while levels of the anti-inflammatory IL-10 increased 
significantly in the 7 MSC-treated patients but not in the controls. All patients have since 
been discharged from the hospital. 
Relevant Animal Studies and Human COPD and ARDS Trials Before COVID 
Animal data 
In a sepsis model in mice, infusion of adipose-derived MSCs into septic animals decreased 
the levels of proinflammatory mediators TNF-α, IL 6, IL1b, IL12, and interferon-gamma 
(IFN-γ), regulated the activation of expressed normal T-cells and secreted regulated upon 
activation, normal T-cell expressed and presumably secreted (RANTES) and macrophage 
inflammatory protein-2 (MIP-2)) and increased IL-10 in the main affected organs. MSC 
infusion also decreased inflammatory infiltration in the peritoneal cavity, lung, liver, and 
intestine and showed an antimicrobial effect by reducing bacterial load in the main affected 
organs.15 In another preclinical study in mice, MSC treatment (1 × 106 cells/animal) 
decreased mortality to 40% in 26 h compared to 100% in the untreated septic group, 
decreased inflammatory cytokines, increased IL -10 and inhibition of apoptosis of 
splenocytes.16 In an endotoxemic rat model, adipose-derived MSC treatment decreased the 
level of inflammatory cytokines in the lung and serum, reduced inflammatory changes in the 
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with pneumonia, MSC treatment showed reduced bacterial counts as a consequence of the 
release of the antimicrobial peptide LL-37 by the cells.18 
Human Clinical Pneumonia, COPD, and ARDS Trials 
Adipose-derived MSCs were studied for ARDS as early as 2014 in a phase I clinical trial of 
20 patients (NCT01902082). The primary objective was the safety of 1 × 106 cells/kg given 
intravenously, and the secondary objectives were efficacy of treating ARDS. While safety 
was established, efficacy was limited likely due to low doses and lack of protocol 
optimization. Recently, a new clinical trial with the same adipose-derived MSCs (SEPCELL) 
for the treatment of bacterial pneumonia has been conducted (NCT03158727). While the 
final efficacy data of the study have not been reported, there have been as of yet no adverse 
events related to the MSCs. Similarly, bone marrow derived MSCs have been used in clinical 
trials of both chronic obstructive pulmonary disease (COPD) and ARDS. In the clinical trials 
of COPD, those with an elevated CRP >4 mg/dL had more significant improvements, 
underscoring the importance in the inflammatory pathway. Three studies have used bone 
marrow-derived MSCs for ARDS, which consistently report that MSCs are safe but have 
disparate efficacy results. A small study by Simonson et al19 administered a single infusion of 
2 x 106/kg bone marrow-derived MSCs to two patients with severe, refractory ARDS, and 
both patients subsequently improved respiratory and hemodynamic function and reversed 
multiorgan failure with subsequent discontinuation of supportive therapy and discharge from 
intensive care. In parallel, multiple pulmonary and systemic markers of inflammation 
measured in bronchoalveolar lavage fluid and blood samples improved. A later phase IIa 
prospective double-blind multicenter clinical trial (ClinicalTrials.gov Identifier: 
NCT02097641) of sixty patients with moderate to severe ARDS reported a 28-day mortality 
rate of 30% in the MSC-treated group compared to 15% in the placebo groups, which was a 
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most results of the most recent phase IIa prospective double-blind multicenter clinical trial 
(ClinicalTrials.gov Identifier: NCT02611609) have not yet been published but were 
presented as an abstract at the American Thoracic Society Meeting in Dallas, Texas, in May 
2019. The MSC group had a lower mortality than the placebo group (25% versus 40%), 
higher number of ventilator-free days, higher number of ICU-free days, and in more severe 
ARDS patients, these results were even more extreme (i.e., mortality 50% versus 25%). The 
therapy was again well tolerated with no serious adverse events related to the treatment 
administration. The same product received a Fast Track Designation from the Food and Drug 
Administration (FDA) in May 2019, and the manufacturer’s partner received an Orphan 
Designation to fast track their ARDS program in November 2019.21 
Mechanism of MSCs 
Immunomodulatory and anti-inflammatory capacity of mesenchymal stem cells 
Several in vitro and in vivo experiments showed local and systemic immunomodulatory 
properties of this kind of cells. At short-term, they modulate the inflammation status, shifting 
from Th1 to Th2 immune response. At long term, they may restore homeostasis through 
generation of immune cells with regulatory phenotype like regulatory T cells (T regulatory), 
regulatory B cells and M2 macrophages.22–24 Furthermore, the activity of adipose-derived 
MSCs in vivo can be modulated through toll-like receptor (TLR) signaling.25 These receptors 
have been linked to rejection and inflammatory diseases (eg, Crohn's disease, rheumatoid 
arthritis, or sepsis), because they can recognize pathogenic or autoantigenic components 
similar to components derived from pathogens or tissue danger signals produced by an injury. 
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Based on these aforementioned properties, MSCs have been used for treatment of complex 
fistula in patients with Crohn's disease. In this clinical setting, they have already shown 
efficacy in the repair and regeneration of damaged tissue and has been included in European 
Crohn’s and Colitis Organization (ECCO) algorithm for CD.27,28 
The differential feature of pulmonary pathology in COVID-19 consisting of massive lung 
inflammation with a cytokine storm and an ICU mortality COVID-19 is characterized by 
increased IL-2, IL-7, granulocyte stimulating factor, interferon-gamma inducible protein 10, 
monocyte chemoattractant protein 1, macrophage inflammatory protein 1a, and tumor 
necrosis factor-α.29 Predictors of mortality in Wuhan, China, were elevated ferritin and IL-6, 
suggesting might be due to a virally driven hyperinflammation. In hyperinflammation, 
immunosuppression is likely to be beneficial.30 This is why a multicenter randomized control 
trial of tocilizumab (Actemra, Roche Holding AG, Basel Switzerland), an anti-IL-6 receptor 
monoclonal antibody was approved for COVID-19 pneumonia in China 
(ChiCTR2000029765). MSCs also inhibit this cytokine storm, specifically IL-1 which 
promotes the release of anti-inflammatory cytokines, increase T regulatory cells, and 
transform M1 (proinflammatory) macrophages into M2 (anti-inflammatory). Furthermore, 
IL-1 activates MSCs towards an anti-inflammatory, revascularization and regenerative 
phenotype in lung tissue.17 This is the reason why its use has been proposed in pulmonary 
sepsis and cystic fibrosis. These are cells that have proven to be very safe when used in a 
similar situation.18 
While MSCs have been administered locally for perianal CD, it has been well established that 
MSCs get trapped in the lungs when administered intravenously and that MSCs migrate to 
sites of inflammation. Thus, taken together, intravenous administration of MSCs is ideally 
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Ongoing Trials Using MSCs to Treat COVID19 Pneumonia 
Four clinical trials are actively enrolling in China using MSCs to treat lung disease after 
SARS-COV2 (Table 2), and we anticipate this to increase as multiple MSC international 
companies are working on single case emergent use, compassionate use, and phase III 
clinical trials to enroll shortly in the United States and Europe. Inclusion criteria are typically 
patients with moderate to severe ARDS without multisystem organ failure. Primary outcomes 
include both safety and efficacy depending on the trial design. Efficacy is most often 
measured as survival, ventilator-free days, and ICU-free days. 
Where We Are Going 
While we are not certain of the clinical efficacy of MSCs for COVID-19, there is significant 
data demonstrating safety. Without alternative therapeutic options in ventilated patients, 
MSCs offer a promising treatment alternative that targets diminishing the cytokine storm and 
resultant immune cell infiltrate. Even if MSCs effectively treat 50% of patients, we have 
won. The application of novel therapeutics should not be confined to any particular field or 
disease states. If we can apply what we have learned to alternative pathologies, we can 
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With permission from Zikuan L, Rongjia Z, Wei H, et al. Transplantation of ACE2- 
mesenchymal stem cells improves the outcome of patients with COVID-19 
pneumonia. Aging Dis. 2020;11:216-228.  
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